Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.

Advertisements

Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.

Dubsky P et al. Proc SABCS 2012;Abstract S4-3.

Use of Oncotype Dx® Testing Breast SSG meeting 10 th July 2015 Dr Rebecca Bowen.

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 The heterogenous landscape of triple-negative breast cancer

Reproduced with permission from Cronin M et al

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 1 Concept of the therapeutic index

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Generations of cancer vaccine antigens

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer Gen Wang, Xiaosong.

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 6 Double opposed-field irradiation of an idealized geometry

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 The imaging biomarker roadmap

Figure 2 Frequency and overlap of alterations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

OncotypeDX DCIS test use and clinical utility: A SEER population-based study Yao Yuan, PhD, MPH, Alison Van Dyke, MD, PhD, Serban Negoita, MD, DrPH & Valentina.

Pre- and post-vorinostat values of ER-related gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of ER-related gene expression.

Molecular signatures are independent of tumor stage and grade.

Figure 1 Gene-expression quantification methods

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.74 Figure 2 Genes evaluated by multigene assays to calculate a recurrence risk score Figure 2 | Genes evaluated by multigene assays to calculate a recurrence risk score. a | The Oncotype DX includes the expression of 21 genes, of which 16 genes are tumour-associated and five serve as controls. b | Prosigna quantifies the expression of 50 classifier genes and five reference genes to categorize breast cancers into one of four intrinsic biological subtypes. c | MammaPrint includes measurements of the expression of 70 genes. d | The Breast Cancer Index includes measures of the ratio of expression of two genes, HOXB13 and IL17BR, in combination with Molecular Grade Index, a five-gene expression assay. e | EndoPredict includes the expression of eight tumour-associated genes and three control genes. Kwa, M. et al. (2017) Clinical utility of gene-expression signatures in early stage breast cancer Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.74